The competitor analysts have labeled ManulifeMFC-- (NYSE: MFC) "fairly valued" with "a full price." I must admit that sounds like a Hold rating dressed up as analysis — the market equivalent of saying the stock is neither here nor there. But the numbers tell a sharper story, and the risk/reward picture isn't as neutral as "fair value" implies.
Here's what's actually happening: Manulife's operating profile has fundamentally improved over the past year. The market has started pricing that in — the stock is up 47% over the trailing year and trading just $1 below its 52-week high — but the quality transformation hasn't been fully credited yet. The setup is better than "fair." It's also not a place to chase.
The growth-and-margin case the market hasn't finished crediting
Quick Backtesting Tool
Manulife's Q2 2026 core EPS grew 16% year-over-year to C$1.09, following Q1 core EPS growth of 11% to C$1.06. Core ROE expanded to 16.3%, up 130 basis points from a year ago. Trailing net profit margins are at 18.5%, up from 15.6% twelve months prior. That margin expansion isn't a one-off — it reflects structural shifts: the business mix is tilting toward higher-quality, fee-based revenues in Asia and Global Wealth & Asset Management, while legacy risk is being actively reduced.
New business CSM (the deferred profit from new insurance policies, which drives future earnings) grew 16% in Q2, and the total CSM balance is up 20% year-over-year to C$27.3 billion. That's a bigger future earnings pipeline, not just a quarter of good news. Asia core earnings jumped 21%. The U.S. core earnings surged 55%, driven by improved long-term care claims experience.
Then came the Munich Re deal: a C$3.2 billion risk transfer covering a block of U.S. long-term care reserves, expected to close in Q4 2026. Long-term care was the historical overhang that capped Manulife's valuation for years. Transferring C$3.2 billion of that risk is the kind of structural de-risking that changes the denominator on valuation multiples.
Valuation: cheaper than it should be, richer than it was
On a trailing basis, Manulife trades at 16.5x earnings — well below Sun Life Financial's 20.5x P/E, despite growing trailing earnings 26% over the past year. The PEG ratio (price-to-earnings divided by growth rate) sits at 0.76x, meaning the stock costs less than one dollar for each dollar of earnings growth. That's below the 1.0x threshold where most growth-at-a-reasonable-price investors draw the line.
The price-to-book ratio of 1.9x is higher than it was a year ago, and one recent article called it "stretched." But that argument ignores that book value per share is growing 15% year-over-year (adjusted book value at C$41.12 per share). The company also returned C$2.6 billion to shareholders through dividends and buybacks in the first half of 2026, with a payout ratio of roughly 51% — sustainable, and leaving room for continued repurchases.
The forward P/E of 23.7x shows the market has started to bake in the growth story. That multiple is not cheap in absolute terms. But relative to a company that's growing core earnings in the mid-teens while expanding margins and de-risking its balance sheet, it's not exorbitant either. The real question isn't whether the stock is "fair." It's whether the quality upgrade has more re-rating to give — and I think it does.
The headwinds you shouldn't ignore
This isn't a one-sided case. Canada core earnings declined 10% in Q2, pressured by unfavorable claims experience and higher expenses supporting group insurance growth. Global Wealth & Asset Management saw net inflows collapse to C$0.4 billion from C$0.9 billion a year earlier, driven by C$4.9 billion in retirement outflows. Institutional inflows of C$6.7 billion kept the total positive, but the flow reversal in retirement and retail is worth watching.
The forward P/E of 23.7x also means the stock is pricing in continued double-digit earnings growth. If execution falters, or if the Canada headwinds deepen, that multiple compresses fast.
Price action: the re-rating has started, so timing matters
Manulife closed at $44.32, trading above both its 50-day moving average ($41.41) and its 200-day moving average ($37.40). The RSI sits at 63.6, firm but not yet at overbought extremes. The MACD line is positive at 0.93, confirming upward momentum. The stock has gained 20.5% over the past 120 days and 22% year-to-date.
The trend is clearly up. But being near a 52-week high changes the entry calculus. You don't chase a stock that has already given you a 47% annual return, even if the thesis is solid. The better risk/reward sits on a pullback toward the 50-day moving average or lower.
The call
Manulife is arguably undervalued relative to its growth trajectory and quality transformation — better than "fair value" suggests. The PEG of 0.76x, the margin expansion, the CSM growth, and the LTC de-risking all point to more re-rating ahead.
But I don't think investors need to chase the rally here. The setup remains constructive, and the fundamentals justify an Upgrade. The better risk/reward for new entries is on a pullback toward the $41–$42 zone. For those who already own the position, hold — the quality story has more to play out. I would reassess if Canada core earnings decline further, if the Munich Re deal encounters regulatory delays, or if wealth management outflows accelerate into a structural flow problem.
Investors awaiting a solid entry into a transforming financial shouldn't let this setup go to waste — but patience on entry is part of the strategy.
